Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
Stock Summary
Top Correlated Resources
4155.TW
Top 10 Correlated ETFs
4155.TW
Top 10 Correlated Stocks
4155.TW
Financial details
Company Rating
Strong Buy
Market Cap
2.46B
Income
147.39M
Revenue
1.52B
Book val./share
18.68
Cash/share
5.11
Dividend
1
Dividend %
3.84%
Employees
-
Optionable
No
Shortable
Yes
Earnings
15 Nov 2022
P/E
22.85
Forward P/E
-
PEG
1574.67
P/S
1.62
P/B
1.39
P/C
5.1
P/FCF
-34.45
Quick Ratio
0.56
Current Ratio
1.74
Debt / Equity
0.22
LT Debt / Equity
0.22
-
-
EPS (TTM)
1.56
EPS next Y
-
EPS next Q
-
EPS this Y
-73.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.23%
Revenue last 5Y
0.49%
Revenue Q/Q
-29.26%
EPS Q/Q
-14.04%
-
-
-
-
SMA20
14.31%
SMA50
4.1%
SMA100
11.84%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
9%
ROC
0.05%
Gross Margin
21%
Oper. Margin
7%
Profit Margin
10%
Payout
64%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
22.1-27.0
52W High
-3.52%
52W Low
+18.41%
RSI
60.27
Rel Volume
0.35
Avg Volume
1.22M
Volume
431.44K
Perf Week
2.16%
Perf Month
13.02%
Perf Quarter
9%
Perf Half Y
12.28%
-
-
-
-
Beta
0.184735
-
-
Volatility
0.24%, 1.49%
Prev Close
-0.19%
Price
26.05
Change
-1.14%
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 18.41 | 14.55 | 16.47 | 17.85 | 12.04 | |
| Net income per share | 1.89 | 2.1 | 1.67 | 1.56 | 0.41 | |
| Operating cash flow per share | 1.53 | 1.67 | 0.6 | 1.78 | 0.21 | |
| Free cash flow per share | 0.22 | 1.3 | -0.43 | 0.82 | -0.62 | |
| Cash per share | 6.81 | 2.4 | 4.41 | 6.82 | 6.15 | |
| Book value per share | 18.01 | 16.22 | 17.12 | 20.79 | 16.25 | |
| Tangible book value per share | 18.01 | 16.47 | 17.27 | 20.91 | 16.23 | |
| Share holders equity per share | 18.01 | 16.22 | 17.12 | 20.79 | 16.25 | |
| Interest debt per share | 5.82 | 3.43 | 7.17 | 3.77 | 5.73 | |
| Market cap | 1.91B | 1.98B | 2.23B | 2.09B | 2.41B | |
| Enterprise value | 1.84B | 2.05B | 2.43B | 1.83B | 2.4B | |
| P/E ratio | 15.07 | 12.25 | 17.71 | 16.09 | 55.39 | |
| Price to sales ratio | 1.55 | 1.76 | 1.79 | 1.41 | 1.91 | |
| POCF ratio | 18.6 | 15.36 | 49.29 | 14.13 | 109.95 | |
| PFCF ratio | 129.74 | 19.7 | -67.94 | 30.74 | -37.29 | |
| P/B Ratio | 1.58 | 1.58 | 1.73 | 1.21 | 1.41 | |
| PTB ratio | 1.58 | 1.58 | 1.73 | 1.21 | 1.41 | |
| EV to sales | 1.49 | 1.83 | 1.96 | 1.23 | 1.9 | |
| Enterprise value over EBITDA | 9.66 | 8.62 | 11.9 | 8.36 | 19.65 | |
| EV to operating cash flow | 17.92 | 15.93 | 53.76 | 12.36 | 109.63 | |
| EV to free cash flow | 125 | 20.44 | -74.09 | 26.89 | -37.18 | |
| Earnings yield | 0.07 | 0.08 | 0.06 | 0.06 | 0.02 | |
| Free cash flow yield | 0.01 | 0.05 | -0.01 | 0.03 | -0.03 | |
| Debt to equity | 0.16 | 0.2 | 0.22 | 0.07 | 0.24 | |
| Debt to assets | 0.36 | 0.31 | 0.41 | 0.31 | 0.39 | |
| Net debt to EBITDA | -0.37 | 0.31 | 0.99 | -1.2 | -0.06 | |
| Current ratio | 1.84 | 2.47 | 1.72 | 1.95 | 2.13 | |
| Interest coverage | 32.45 | 26.73 | 17.82 | 16.8 | 1.83 | |
| Income quality | 0.81 | 0.8 | 0.36 | 1.14 | 0.5 | |
| Dividend Yield | 0.05 | 0.06 | 0.07 | 0.05 | 0.05 | |
| Payout ratio | 0.79 | 0.69 | 1.32 | 0.86 | 3.03 | |
| Sales general and administrative to revenue | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | |
| Research and developement to revenue | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.86 | -0.22 | -1.73 | -0.54 | -3.95 | |
| Capex to revenue | -0.07 | -0.03 | -0.06 | -0.05 | -0.07 | |
| Capex to depreciation | -3.76 | -0.94 | -1.88 | -1.59 | -1.55 | |
| Stock based compensation to revenue | 0.01 | 0.01 | 0 | 0 | 0 | |
| Graham number | 27.7 | 27.65 | 25.35 | 27.01 | 12.31 | |
| ROIC | 0.09 | 0.09 | 0.07 | 0.07 | 0.01 | |
| Return on tangible assets | 0.07 | 0.09 | 0.06 | 0.05 | 0.02 | |
| Graham Net | -1.95 | -3.4 | -5.35 | -0.66 | -2.64 | |
| Working capital | 404.38M | 477.71M | 434.17M | 622.15M | 788.44M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
| Net current asset value | 208.97M | 220.04M | 118.97M | 479.65M | 379.25M | |
| Invested capital | 0.32 | 0.21 | 0.41 | 0.18 | 0.35 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 176.13M | 201.48M | 213.7M | 205.67M | 222.09M | |
| Average inventory | 265.95M | 310.81M | 357.23M | 349.07M | 362.35M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 56.62 | 88.01 | 85.63 | 64.8 | 80.87 | |
| Days of inventory on hand | 70.62 | 121.58 | 141.11 | 109.98 | 127.36 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 6.45 | 4.15 | 4.26 | 5.63 | 4.51 | |
| Inventory turnover | 5.17 | 3 | 2.59 | 3.32 | 2.87 | |
| ROE | 0.11 | 0.13 | 0.1 | 0.08 | 0.03 | |
| Capex per share | -1.31 | -0.37 | -1.03 | -0.96 | -0.82 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 3.23 | 4.44 | 4.45 | 4.62 | 3.26 | |
| Net income per share | 0.16 | -0.02 | 0.52 | 0.57 | 0.49 | |
| Operating cash flow per share | 0.18 | 1.82 | -0.4 | 0.38 | 0.69 | |
| Free cash flow per share | -0.13 | 1.76 | -0.6 | 0.06 | -1.72 | |
| Cash per share | 5.82 | 8.01 | 5.53 | 6.26 | 5.11 | |
| Book value per share | 17.72 | 21.17 | 18.41 | 18.08 | 18.68 | |
| Tangible book value per share | 17.75 | 21.15 | 18.36 | 18.01 | 18.18 | |
| Share holders equity per share | 17.72 | 21.17 | 18.41 | 18.08 | 18.68 | |
| Interest debt per share | 6.8 | 7.4 | 5.73 | 6.34 | 9.17 | |
| Market cap | 2.28B | 1.88B | 2.15B | 2.22B | 2.4B | |
| Enterprise value | 2.42B | 1.87B | 2.2B | 2.27B | 2.82B | |
| P/E ratio | 37.34 | -329.13 | 11.01 | 10.33 | 12.96 | |
| Price to sales ratio | 7.39 | 5.25 | 5.14 | 5.1 | 7.79 | |
| POCF ratio | 130.55 | 12.85 | -57.91 | 62.13 | 36.89 | |
| PFCF ratio | -178.34 | 13.24 | -38.43 | 419.68 | -14.74 | |
| P/B Ratio | 1.35 | 1.1 | 1.24 | 1.3 | 1.36 | |
| PTB ratio | 1.35 | 1.1 | 1.24 | 1.3 | 1.36 | |
| EV to sales | 7.83 | 5.23 | 5.28 | 5.2 | 9.16 | |
| Enterprise value over EBITDA | 70.02 | 102.58 | 27.46 | 25.19 | 37.83 | |
| EV to operating cash flow | 138.36 | 12.8 | -59.49 | 63.41 | 43.38 | |
| EV to free cash flow | -189.02 | 13.19 | -39.48 | 428.38 | -17.33 | |
| Earnings yield | 0.01 | 0 | 0.02 | 0.02 | 0.02 | |
| Free cash flow yield | -0.01 | 0.08 | -0.03 | 0 | -0.07 | |
| Debt to equity | 0.24 | 0.24 | 0.23 | 0.24 | 0.22 | |
| Debt to assets | 0.39 | 0.39 | 0.37 | 0.41 | 0.41 | |
| Net debt to EBITDA | 3.95 | -0.38 | 0.73 | 0.51 | 5.66 | |
| Current ratio | 2.17 | 2.13 | 2.32 | 2 | 1.74 | |
| Interest coverage | 2.03 | 0.95 | 12.48 | 21.39 | 7.69 | |
| Income quality | 1.14 | -102.44 | -0.76 | 0.67 | 1.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0.01 | |
| Capex to operating cash flow | -1.73 | -0.03 | 0.51 | -0.85 | -3.5 | |
| Capex to revenue | -0.1 | -0.01 | -0.05 | -0.07 | -0.74 | |
| Capex to depreciation | -2.2 | -0.3 | -1.15 | -1.83 | -13.47 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.99 | 2.91 | 14.68 | 15.23 | 14.35 | |
| ROIC | 0 | 0 | 0.02 | 0.03 | 0.01 | |
| Return on tangible assets | 0.01 | 0 | 0.02 | 0.02 | 0.02 | |
| Graham Net | -3.56 | -3.44 | -3.57 | -4.54 | -5.97 | |
| Working capital | 777.18M | 788.44M | 813.1M | 792.64M | 635.18M | |
| Tangible asset value | 0 | 0 | 0 | 0 | 1.72B | |
| Net current asset value | 360.41M | 379.25M | 401.1M | 389.79M | 246.23M | |
| Invested capital | 0.38 | 0.35 | 0.31 | 0.35 | 0.49 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 183.56M | 228.2M | 209.61M | 217.88M | 189.15M | |
| Average inventory | 357.86M | 362.02M | 350.05M | 348.4M | 372.47M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 50.45 | 70.07 | 55.33 | 61.14 | 60.29 | |
| Days of inventory on hand | 124.17 | 110.36 | 96.65 | 97.77 | 149.03 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.78 | 1.28 | 1.63 | 1.47 | 1.49 | |
| Inventory turnover | 0.72 | 0.82 | 0.93 | 0.92 | 0.6 | |
| ROE | 0.01 | 0 | 0.03 | 0.03 | 0.03 | |
| Capex per share | -0.32 | -0.05 | -0.2 | -0.32 | -2.41 |
Frequently Asked Questions
What is OK Biotech Co., Ltd. stock symbol ?
OK Biotech Co., Ltd. is a US stock and trading under the symbol 4155.TW
What is OK Biotech Co., Ltd. stock quote today ?
OK Biotech Co., Ltd. stock price is $26.05 today.
Is OK Biotech Co., Ltd. stock public?
Yes, OK Biotech Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.22M
- Market Capitalization 2.46B
- Headquarters Hsinchu City,US
- IPO Date 2012-06-20
-
Website
https://www.okbiotech.com 
OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. It also provides nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
